NCT03123211 2022-05-24
Expanded Access to Veliparib
AbbVie
No longer available
Clinical Trials
11 trialsNCT05108740 2021-12-09
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
Novartis
No longer available
NCT02985658 2021-07-21
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
University of Washington
No longer available
NCT03706573 2021-07-19
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
Novartis
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT02142868 2018-12-21
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Pfizer
No longer available
NCT03067935 2018-05-21
Individual Patient Expanded Access-Glembatumumab Vedotin
Celldex Therapeutics
No longer available
NCT01120561 2017-02-15
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Genentech, Inc.
No longer available
NCT01626781 2013-10-22
PROCAPP
AIO-Studien-gGmbH
No longer available
NCT01130259 2013-09-17
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
Sanofi
No longer available